To hear about similar clinical trials, please enter your email below
Trial Title:
The Efficacy of Combining Platelet-rich Plasma With Crystallized Phenol in Pilonidal Sinus Disease
NCT ID:
NCT06324656
Condition:
Pilonidal Sinus
Conditions: Official terms:
Pilonidal Sinus
Paranasal Sinus Diseases
Phenol
Conditions: Keywords:
pilonidal sinus
Children
platelet rich plasma
Study type:
Interventional
Study phase:
N/A
Overall status:
Recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Treatment
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Intervention:
Intervention type:
Procedure
Intervention name:
crystallized phenol + platelet rich plasma application
Description:
At our pilonidal care clinic, patients will undergo a comprehensive treatment regimen
starting with manual or laser hair removal to reduce hair by over 90%. For pilonidal
abscesses, we will perform incision, drainage, and antibiotic therapy. Treatments will
include local anesthesia with lidocaine and epinephrine, thorough disinfection with
povidone-iodine, and wound irrigation. Sinuses will be treated by removing hair and
curettage, followed by protective ointment application and crystallized phenol to fill
the cavity, ensuring precise dosing and safety.
For enhanced healing, crystallized phenol + platelet-rich plasma application patients
will receive platelet-rich plasma injections to minimize infection risk and promote
tissue regeneration, all under strict sterilization to maintain cleanliness and efficacy.
Arm group label:
Crystallized phenol + platelet rich plasma
Intervention type:
Procedure
Intervention name:
crystallized phenol
Description:
At our pilonidal care clinic, patients will undergo a comprehensive treatment regimen
starting with manual or laser hair removal to reduce hair by over 90%. For pilonidal
abscesses, we will perform incision, drainage, and antibiotic therapy. Treatments will
include local anesthesia with lidocaine and epinephrine, thorough disinfection with
povidone-iodine, and wound irrigation. Sinuses will be treated by removing hair and
curettage, followed by protective ointment application and crystallized phenol to fill
the cavity, ensuring precise dosing and safety.
Arm group label:
Crystallized phenol
Summary:
The use of local liquid phenol for pilonidal sinus disease was first introduced by
Maurica and Greenwood in 1964. Phenol, also known as carbolic acid, has been proven to be
an effective sclerosing agent for treating pilonidal sinus diseas. Its antiseptic and
anesthetic qualities make it suitable for application in awake patients under local
anesthesia. The treatment of pilonidal sinus diseas in children with crystallized phenol
was first published by Ateş et al in 2018. However, the treatment involving only
crystallized phenol can require numerous sessions, potentially extending the duration of
the treatment. IIn this study, the investigators, investigated whether the application of
platelet-rich plasma following crystallized phenol treatment could accelerate the healing
process and reach better outcomes. This study evaluates the efficacy of PRP as a
treatment modality for pilonidal sinus disease in pediatric patients.
Detailed description:
Upon their arrival at our pilonidal care clinic, patients commenced a regimen of manual
shaving of the gluteal cleft either weekly or bi-weekly. Laser epilation therapy was
initiated at the earliest opportunity, conducted every 6 to 8 weeks, aiming for a hair
reduction of over 90%. For patients presenting with a pilonidal abscess, an initial
procedure of incision and drainage was performed, followed by antibiotic therapy. In the
outpatient clinic, patients were placed in a prone position, and the area was sterilized
with a povidone-iodine solution.
Anaesthesia local: The skin and subcutaneous tissues surrounding the PSD area, including
the sinus openings, receive local anesthesia with 5 ml of lidocaine (20 mg/ml) mixed with
epinephrine (0.0125 mg/ml).
Zone keeps clean: The area surrounding the PSD is thoroughly disinfected with
povidone-iodine solution, covering a minimum area of 20 square centimeters to ensure
adequate local disinfection.
Irrigation with isotonic solution: The wound is washed with sterile isotonic solution.
Zero hair (removing hair and curettage): For sinuses measuring ≤ 3 mm in diameter,
dilation is performed using a mosquito clamp (BH-109, Aesculap®, Center Valley, PA, USA).
Hair within the sinus is removed. After the complete removal of hair from the area, the
granulation tissue is then excised through curettage.
Ointment application around the wound: To prevent skin necrosis and burns, a 0.2%
nitrofurazone (Furacin® Eczacıbası İlaç San, Istanbul, Turkey) ointment is meticulously
applied around the pilonidal sinus area immediately before the CP application, ensuring a
protective barrier and enhancing skin safety.
Gravel-like crystallized phenol application: In this instance, the phenol applied is not
in liquid form; rather, it is in a solid, gravel-like form. CP (BotaFarma İlaç Medikal
İtriyat Kimya San. Tic. Ltd. Şti, Ankara, Turkey) is carefully administered into the
cavity via the orifice, with the precise amount required just sufficient to fill the
cavity without causing any overflow. This step necessitates meticulous attention to
ensure the correct dosage and prevent any potential spillage. Typically, for an average
pediatric patient and the size of the defect encountered, an amount ranging from 4 to 6
grams of phenol is deemed adequate to effectively treat the area while minimizing risk.
Local re-disinfection prior to PRP injection: Up to this point, all procedures are
identical for both groups. However, the following steps and any subsequent applications
are exclusively for Group 2. The area around the pilonidal sinus should be thoroughly
disinfected again with povidone-iodine (care should be taken to prevent povidone-iodine
from entering the sinus itself). This step is critical because, following this phase, a
PRP injection will be administered into the tissue, necessitating that the skin is
properly disinfected to minimize the risk of infection.
Undergo PRP injection: In Group 2, patients received a PRP injection during the same
session as the CP application. The amount of PRP injected-approximately 1-2 ml, depending
on the size of the pilonidal sinus-was administered around the edges and surrounding area
of the wound.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
The study will be included patients with pilonidal sinus disease aged between 0 to 18
years.
Exclusion Criteria:
Patients who had undergone prior pilonidal sinus disease surgery or had anomalies in the
sacrococcygeal region will be excluded from the study. Additionally, patients who will
decline to participate in the study or will be failed to attend post-procedural
outpatient follow-ups will also be excluded.
Gender:
All
Minimum age:
1 Day
Maximum age:
18 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Mustafa Azizoğlu
Address:
City:
Istanbul
Zip:
34430
Country:
Turkey
Status:
Recruiting
Contact:
Last name:
Mustafa Azizoğlu
Phone:
+905447448244
Email:
mdmazizoglu@gmail.com
Start date:
November 21, 2023
Completion date:
September 30, 2024
Lead sponsor:
Agency:
Necmi Kadıoğlu Hospital
Agency class:
Other
Source:
Necmi Kadıoğlu Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06324656